Examines issues related to drug safety in the context of the regulatory process that Congress and the FDA have established for ensuring that drugs are safe and effective. Describes FDA process for approving new drugs, and examines FDA and industry role in postmarket regulation of approved drugs. Discusses problems in identifying and resolving postmarketing safety and effectiveness issues, and outlines FDA and Congressional options for improving postmarket activities.
ProQuest U.S. Congressional Research Digital Collection
Note
Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed Dec. 2010). Reuse except for individual research requires license from ProQuest, LLC. CRS Report. AVAILABLE ONLINE TO AUTHORIZED PSU USERS.